PBMs Must Pass On, not Pocket, Drug-Price Savings

Some pharmaceutical companies have recently cut the costs of name-brand drugs and offered discounted generics, but those savings are often not reaching consumers. Instead, the savings are being pocketed as inflated profits by PBMs (pharmacy benefit managers). The Senate Finance Committee's hearing earlier this week pressed executives from PBMs to explain why they are not passing on savings from lower drug prices to consumers, but more must be done to ensure this type of activity does not go unchecked.